Navigation Links
Bronchial thermoplasty shows long-term effectiveness for asthma
Date:12/2/2013

DENVER The beneficial effects of bronchial thermoplasty, a non-pharmacologic treatment for asthma, last at least five years, according to researchers at National Jewish Health and other institutions. The therapy, in which heat is applied to a patient's airways during a bronchoscopy procedure, was approved by the U.S. Food and Drug Administration in April 2010. Among other criteria, the researchers report in the December issue of the Journal of Allergy and Clinical Immunology that reductions in severe asthma exacerbations, emergency department visits, medication use and missed workdays continued out to five years after the procedure was performed.

"These data add to the growing body of evidence that bronchial thermoplasty has a long-term benefit and is an important option for patients whose moderate to severe asthma is not controlled by medications," said Michael Wechsler, MD, lead author of the study and professor of medicine at National Jewish Health.

During bronchial thermoplasty a physician uses a specialized bronchoscope to apply radio frequency energy to heat the airways. The treatment is done in three separate procedures approximately three weeks apart, and reduces smooth muscle surrounding the airways, which can constrict and reduce airflow in asthma.

Earlier research showed that most patients who underwent bronchial thermoplasty in the AIR2 trial experienced benefits for at least two years. The current study extends that to five years.

In the year before bronchial thermoplasty, 52 percent of patients suffered severe exacerbations of their asthma. That dropped to 31 percent in the first year following the treatment and averaged 29 percent over the five years following the procedure.

After bronchial thermoplasty 78 percent fewer patients made visits to the emergency department, dropping from about 30 percent of patients to less than 7 percent.

Missed workdays dropped 66 percent in the five years after bronchial thermoplasty. Average use of corticosteroid medications also dropped 17 percent.

Stable rates of respiratory adverse events and respiratory-related hospitalizations as well as unchanged CT scans in years two through five indicated that there were no significant safety concerns with the procedure.


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 18, 2017 , ... ... commercialization, has just announced two more sessions of its “From the Helm” Webinar ... management activities. Led by David Cronin, Cognition’s CEO, the half-hour public webinars will ...
(Date:7/18/2017)... PA (PRWEB) , ... July 18, 2017 , ... An ... control excessive sweating. "Due to menopause, I have frequent hot flashes, and I suffer ... effective but inconspicuous way to keep cool while out and about." INSTA-FAN meets that ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... FCPX LUT ... cooler tones any media. FCPX LUT Berlin includes 60 different color-grade presets, giving FCPX ... distorted looks, vignettes and blurs to emphasize each subject, plus much more. FCPX LUT ...
(Date:7/17/2017)... Greenwich, Connecticut (PRWEB) , ... July 17, 2017 ... ... not too late for parents and camp staff to ensure children are protected ... of Lyme disease this year, children are at an increased risk not only ...
(Date:7/17/2017)... ... 17, 2017 , ... Jordan Search Consultants (JSC), a national ... for Springfield Clinic’s Chief Executive Officer (CEO) in Springfield, IL. Working with JSC ... with more than 30 years of experience, as the new CEO. , ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the ... The research describes the use of its AVACEN Treatment Method ... suffering from fibromyalgia. ... AVACEN Medical ... characterized by chronic widespread pain. It affects approximately 200 to 400 million ...
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
Breaking Medicine Technology: